NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--
BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News.
Rasheda Ali, a member of BrainStorms advisory board and revered author and daughter of renowned boxer Muhammad Ali, discussed BrainStorms promising ALS clinical trials last week on NBC NY and Current TVs Viewpoint. She was also interviewed on Fox News Geraldo at Large and Neil Cavuto shows.
In her various interviews, Ms. Ali stated that BrainStorms Phase I/II ALS clinical trial results with its NurOwn stem cell candidate exceeded scientists expectations, surpassing the goal of confirming safety by also showing initial signs of clinical improvement. She also discussed BrainStorms recent acceleration to a Phase IIa trial by the Israeli Ministry of Health.
Ms. Alis interviews can be viewed at the following links:
NBC NY: http://bit.ly/Xam0rG.
Current TV Viewpoint: http://bit.ly/13VDZRY
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.
Safe Harbor Statement
Read the original here:
Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations